Daratumumab and Hyaluronidase-fihj

Molecule Name: Daratumumab and Hyaluronidase-fihj
Active Ingredient: daratumumab and hyaluronidase-fihj
Dosage Form: 1800mg & 30000 Units/ 15ml
Manufacturer Name:

Daratumumab and hyaluronidase are now used together or in combination to assist patients with certain types of multiple myeloma or light chain amyloidosis. It is also being researched as a treatment for other forms of cancer. Daratumumab binds to a protein called CD38, which is found on immune cells and cancer cells alike, including myeloma cells. 

Daratumumab may inhibit CD38 and assist the immune system in destroying cancer cells. Daratumumab can be administered via injection under the skin thanks to hyaluronidase. Daratumumab and Hyaluronidase-fihj is administered in less time than daratumumab alone, which is administered as an infusion. Daratumumab is also known as hyaluronidase.

website background

How Darzalex faspro can benefit people?

Darzalex or Darzalex Faspro has been studied in both newly diagnosed and relapsed/refractory multiple myeloma patients. Darzalex/Darzalex Faspro studies in myeloma patients have included the mentioned patient populations:

  • Patients who have previously received multiple therapies (heavily pre-treated)
  • Patients with impaired renal function (renal impairment)
  • Patients who are not candidates for stem cell transplantation
  • Patients who had failed both PIs and IMiDs
  • Patients who have mildly impaired liver function (mild hepatic impairment)

Mechanism of Working

In myeloma cells, the drug Darzalex Faspro interacts to the protein CD38 (this protein is also found on other cells, such as red blood cells). It is believed to reduce the growth of myeloma cells in a number of ways, including by assisting the immune system in finding and eliminating myeloma cells.

A monoclonal antibody called Darzalex can be given to patients in one of two ways: either as an intravenous (IV) infusion or as a subcutaneous (SC) injection (that is, under the skin).

What could be the possible side effects of Darzalex Faspro?

When a patient has an adverse reaction to an infusion, their Darzalex Faspro infusion is stopped, and their symptoms are handled. The infusion may be restarted at a slower rate after the symptoms go away. Those who have several severe responses or a life-threatening infusion reaction stop using Darzalex.

Low neutrophil, platelet, lymphocyte, red blood cell, and haemoglobin counts are the most frequent significant adverse effects. Other issues include:

About Us

HAYAT ALHIKMAH, a pharmaceutical consultant in Dubai, is here to assist you in fulfilling all your medical requirements. We can assist in procuring medicines like Daratumumab and Hyaluronidase-fihj. We offer quality assurance.

We have a strong commitment to consult in availing the highest-quality pharmaceuticals and medications. Our team is here to help you every step of the way and make sure that your requirements get fulfilled as soon as possible. Our team of specialists are extremely skilled and knowledgeable about various medications. 

0 +


0 +

Ware House

0 +



Person suffering from the following should not take Daratumumab and Hyaluronidase-fihj

  • decreased platelets in the blood 
  • low levels of neutrophils, a type of white blood cell 
  • Hepatitis B infection reactivation 
  • pregnancy

Store Daratumumab and Hyaluronidase-fihj vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light. Do not freeze or shake.

Daratumumab and Hyaluronidase-fihj was tested in eight clinical trials for its efficacy in treating multiple myeloma, both alone and in combination with other cancer-fighting drugs. The study found that when Daratumumab and Hyaluronidase-fihj was added to standard cancer treatments, it was more effective than when these standard treatments were given alone.

Daratumumab and Hyaluronidase-fihj may be given as an IV infusion along with Velcade, melphalan, and prednisone (D-VMP), Velcade, Thalomid (thalidomide, Celgene), and dexamethasone (D-VTd), or Revlimid and dexamethasone (D-VTd) for newly diagnosed multiple myeloma (DRd). Daratumumab and Hyaluronidase-fihj should be administered at a dose of 16 mg/kg body weight. 

Daratumumab and Hyaluronidase-fihj is administered weekly from weeks 1 to 6, every three weeks from weeks 7 to 54, and every four weeks until disease progression during the D-VMP regimen.

• Tiredness
• nausea
• diarrhoea
• breathing difficulties
• insomnia
• muscle spasms
• fever, and headache
• back pain
• vomiting
• upper respiratory infection with elevated blood pressure